Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17153800 | 0.97 | FBP1 (0.94) | FBP1ALDH1A1SMN1; SMN2GAAMAPK1 | |
| SCHEMBL750885 | 0.78 | — | — | |
| SCHEMBL173266 | 0.78 | — | — | |
| SCHEMBL9087747 | 0.78 | — | — | |
| SCHEMBL15362563 | 0.76 | ALDH1A1 (0.68) | FBP1ALDH1A1SMN1; SMN2GAAMAPK1 | |
| SCHEMBL28259234 | 0.76 | FBP1 (0.61) | FBP1ALDH1A1SMN1; SMN2GAAMAPK1 | |
| SCHEMBL11787926 | 0.73 | FBP1 (0.55) | FBP1ALDH1A1SMN1; SMN2GAAMAPK1 | |
| SCHEMBL65180 | 0.73 | — | — | |
| SCHEMBL6530544 | 0.73 | ALDH1A1 (0.57) | FBP1ALDH1A1GAAMAPK1MEN1 | |
| SCHEMBL94572 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | claimed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | claimed |
| EP-3094619-B1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | MASSACHUSETTS GEN HOSPITAL (US) | 2019-07-31 | — | — | EP | claimed |
| EP-3094619-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2016-11-23 | — | — | EP | claimed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | claimed |
| WO-2015106240-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION (US) | 2015-07-16 | — | — | WO | claimed |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | disclosed |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | disclosed |
| US-10640630-B2 | Elastomeric composites containing modified fillers and functionalized elastomers | CABOT CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| EP-2819854-B1 | ELASTOMERIC COMPOSITES CONTAINING MODIFIED FILLERS AND FUNCTIONALIZED ELASTOMERS | CABOT CORP (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3094619-B1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | MASSACHUSETTS GEN HOSPITAL (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2013130099-A1 | ELASTOMERIC COMPOSITES CONTAINING MODIFIED FILLERS AND FUNCTIONALIZED ELASTOMERS | CABOT CORPORATION (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130165560-A1 | Modified Fillers And Elastomeric Composites Comprising Same | CABOT CORPORATION (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012031183-A2 | MODIFIED FILLERS AND ELASTOMERIC COMPOSITES COMPRISING SAME | CABOT CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2010123997-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123997-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010030811-A2 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030811-A2 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | HIF1AN, HBG2, HIF1A | FBP1 1435/4885ALDH1A1 2214/4885SMN1; SMN2 1069/4885 |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | HIF1AN, HBG2, HIF1A | FBP1 1435/4885ALDH1A1 2214/4885SMN1; SMN2 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.